Mexican president taps Maria del Carmen Bonilla as deputy finance minister
MEXICO CITY (Reuters) - Mexican President Claudia Sheinbaum has nominated Maria del Carmen Bonilla as deputy finance minister, putting to rest weeks of speculation about who will assume the post.
Bonilla, one of several candidates, has overseen the ministry's public credit and international affairs unit since 2021.
A congressional committee will vote on Bonilla's nomination on Wednesday, according to a congressional agenda. If confirmed, she will occupy the position vacated in March by Edgar Amador, when Sheinbaum appointed him Mexico's finance minister.
According to Mexican newspaper El Economista, Bonilla oversaw the issuance of a $12 billion debt offering to support state-owned oil company Pemex.
Bonilla holds a degree in finance from the Universidad Anahuac in Mexico City. She previously served as investment coordinator for the Mexican Social Security Institute and as an asset manager and trader.
(Reporting by Raúl Cortés Fernández; Writing by Brendan O'Boyle and Benjamín Mejías Valencia; editing by Cassandra Garrison and Emily Green)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Star
34 minutes ago
- The Star
DeepSeek's launch of new AI model delayed by Huawei chip issues, FT reports
FILE PHOTO: A DeepSeek AI sign is seen at a building where the Chinese start-up's office is located in Beijing, China, February 19, 2025. REUTERS/Florence Lo/File Photo
New Straits Times
4 hours ago
- New Straits Times
US pharma tariffs likely weeks away, sources say
WASHINGTON: The announcement by President Donald Trump's administration of the results of a probe into pharmaceutical imports and new sector-specific US tariffs likely remains weeks away, four official and industry sources said, later than initially promised as he focuses on other matters. Commerce Secretary Howard Lutnick had said in April when the review of whether reliance on foreign drug production threatens US national security was launched that he anticipated that it would conclude between mid-May and mid-June. Global pharmaceutical companies are bracing for the outcome of the investigation, which will usher in sector-specific tariffs that Trump has said could start small and eventually rise to 250 per cent. The Republican president said as recently as last week that his plan relies on phased-in tariffs, giving drugmakers time to increase manufacturing in the United States as he pushes to alter what he says are global trade distortions in many industries. One government official in Europe and a source with knowledge of the White House process, as well as two sources at European drug firms familiar with the process, told Reuters that the report and tariffs announcement was not imminent and likely weeks away. These sources spoke on condition of anonymity. A White House spokesperson, asked about media reporting indicating that the results of the probe could be several weeks away, cautioned that such reports were pure speculation unless confirmed by the White House. The spokesperson declined to give further details about the timing of the pharma probe or one involving semiconductors. The investigation is examining pharmaceutical imports ranging from finished prescription drugs to active pharmaceutical ingredients, called APIs, and other raw materials, with the results to be disclosed in a Commerce Department report. Lutnick said last month the tariff plan that will be based on the report would be completed by the end of July. Lutnick then said on July 29 it would be two more weeks. The investigation was launched under Section 232 of the Trade Expansion Act of 1962. While the investigation is ongoing, the pharmaceutical sector has been exempted from the sweeping tariffs imposed by the Trump administration. The United States has reached bilateral trade deals with the UK, Japan, South Korea and the European Union that promised more favorable terms for their pharma exports than those expected to be levied on the sector globally. A European government official said that an announcement before the end of August appears unlikely but cautioned that the timeline could shift depending on other developments. A source at a European drugmaker said the Trump administration is focused on the US-Russia summit in Alaska on Friday and therefore no announcement is expected this week. The source familiar with the White House process said that announcement is unlikely to come this week given other priorities. That source and one other source said that they expect the Trump administration to announce the results of its national security investigation into semiconductors first, followed by the pharma announcement, putting it a few weeks away. The Section 232 provision authorizes the president to adjust imports - including imposing tariffs - if a category of goods is being imported into the United States in quantities that "threaten or impair the national security." Medical goods historically have been spared from trade wars due to the potential harm to patient access, and drugmakers have said tariffs could undercut other health policy goals outlined by the Trump administration, including lowering drug prices. US tariffs on imported pharmaceutical products would mark the latest in a series of sectoral tariffs announced by the administration, following metals and cars, that some economists have predicted will drive up costs for American consumers.
The Star
4 hours ago
- The Star
Chinese PC maker Lenovo fiscal Q1 profit doubles, revenue up 22%
An employee gestures next to a Lenovo logo at Lenovo Tech World in Beijing, China November 15, 2019. REUTERS/Jason Lee/File photo BEIJING: China's Lenovo on Thursday reported a 108% rise in first-quarter profit despite challenges from U.S. tariff policies. Net profit attributable to shareholders was $505 million, above the consensus estimate of $307.7 million. Overall revenue at the world's largest personal computer maker for the three months ended June 30 climbed 22% year-on-year to $18.8 billion , ahead of analysts' expectations of $17.4 billion, according to LSEG data. The U.S. and China have extended a tariff pause for another 90 days, averting triple-digit duties on each other's goods and offering temporary relief to businesses on both sides. Despite the truce, Chinese exports to the U.S. - including PCs - currently face a 30% levy, while U.S. exports to China face a 10% tariff. - Reuters Trading ideas: Yinson, Iris, MR DIY, ES Sunlogy, Avangaad, Magma, PetChem, VSTECS, Master-Pack, RCE Capital, Eonmetall
